Who are Epalrestat,Mecobalamin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/epalrestat-mecobalamin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Epalrestat,Mecobalamin — Competitive Intelligence Brief

Epalrestat,Mecobalamin (Epalrestat,Mecobalamin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostacyclin analog + Cobalamin derivative combination. Area: Neurology / Peripheral Neuropathy.

marketed Prostacyclin analog + Cobalamin derivative combination Prostacyclin receptor (IP receptor) + Methylcobalamin-dependent enzymes Neurology / Peripheral Neuropathy Small molecule Live · refreshed every 30 min

Target snapshot

Epalrestat,Mecobalamin (Epalrestat,Mecobalamin) — Xiangya Hospital of Central South University. Epalrestat is a prostacyclin analog that inhibits platelet aggregation and improves microcirculation, while mecobalamin is a cobalamin derivative that supports nerve function and myelin formation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Epalrestat,Mecobalamin TARGET	Epalrestat,Mecobalamin	Xiangya Hospital of Central South University	marketed	Prostacyclin analog + Cobalamin derivative combination	Prostacyclin receptor (IP receptor) + Methylcobalamin-dependent enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostacyclin analog + Cobalamin derivative combination class)

Xiangya Hospital of Central South University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Epalrestat,Mecobalamin — Competitive Intelligence Brief. https://druglandscape.com/ci/epalrestat-mecobalamin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab